Get the Stockscreener App
19.72
7.59%
-1.62
After Hours:
19.72
Sarepta Therapeutics Inc stock is traded at $19.72, with a volume of 2.84M.
It is down -7.59% in the last 24 hours and down -17.87% over the past month.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
See More
Previous Close:
$21.34
Open:
$20.845
24h Volume:
2.84M
Relative Volume:
0.49
Market Cap:
$2.07B
Revenue:
$2.48B
Net Income/Loss:
$-57.96M
P/E Ratio:
-26.00
EPS:
-0.7585
Net Cash Flow:
$-453.97M
1W Performance:
+4.28%
1M Performance:
-17.87%
6M Performance:
-47.55%
1Y Performance:
-85.21%
1-Day Range:
$19.67
$21.00
1-Week Range:
$18.73
$21.38
52-Week Range:
$10.41
$132.65
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Name
Sarepta Therapeutics Inc
Sector
Industry
Phone
617-274-4000
Address
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
19.72 | 2.24B | 2.48B | -57.96M | -453.97M | -0.7585 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.60 | 110.02B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.11 | 82.00B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.56 | 59.61B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
894.90 | 56.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
211.41 | 44.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-25 | Upgrade | Mizuho | Neutral → Outperform |
| Sep-22-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-29-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-25 | Initiated | Bernstein | Mkt Perform |
| Jul-29-25 | Reiterated | H.C. Wainwright | Sell |
| Jul-29-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Jul-29-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-28-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Jul-25-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-25 | Initiated | Citigroup | Sell |
| Jul-23-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-22-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jul-21-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-21-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-21-25 | Downgrade | Mizuho | Outperform → Neutral |
| Jul-21-25 | Downgrade | Needham | Hold → Underperform |
| Jul-21-25 | Downgrade | UBS | Buy → Neutral |
| Jul-18-25 | Downgrade | Needham | Buy → Hold |
| Jun-20-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-18-25 | Downgrade | TD Cowen | Buy → Hold |
| Jun-17-25 | Initiated | Wolfe Research | Peer Perform |
| Jun-16-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-16-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-16-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-16-25 | Downgrade | H.C. Wainwright | Neutral → Sell |
| Jun-16-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-16-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-06-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| May-08-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-11-25 | Initiated | Wells Fargo | Overweight |
| Apr-02-25 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Mar-31-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Nov-27-24 | Reiterated | Needham | Buy |
| Nov-25-24 | Initiated | H.C. Wainwright | Sell |
| Nov-07-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jul-29-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-26-24 | Downgrade | Citigroup | Buy → Neutral |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| May-28-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-13-23 | Resumed | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-21-23 | Initiated | Wedbush | Outperform |
| Oct-31-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-31-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-23-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-04-23 | Initiated | Citigroup | Buy |
| Mar-01-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-22-22 | Reiterated | BTIG Research | Buy |
| Dec-16-22 | Upgrade | UBS | Neutral → Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-05-22 | Reiterated | Needham | Buy |
| Dec-09-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-21 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Jan-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-11-21 | Downgrade | UBS | Buy → Neutral |
| Jan-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Jan-08-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-31-20 | Initiated | Mizuho | Buy |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Aug-21-19 | Reiterated | Needham | Buy |
| Jul-09-19 | Reiterated | Morgan Stanley | Overweight |
| Jul-01-19 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-11-19 | Reiterated | Credit Suisse | Outperform |
| Oct-12-18 | Initiated | Bernstein | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-26-18 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-14-18 | Resumed | BofA/Merrill | Buy |
| Sep-06-18 | Initiated | Credit Suisse | Outperform |
| Aug-01-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-21-18 | Reiterated | Robert W. Baird | Outperform |
| Jun-20-18 | Reiterated | Needham | Buy |
| Jun-19-18 | Reiterated | H.C. Wainwright | Buy |
View All
Sarepta Therapeutics Inc Stock (SRPT) Latest News
How Do Sarepta (SRPT)’s Enhanced Safety Moves Reflect Its Approach to Long-Term Risk Management? - Yahoo Finance
Sarepta Therapeutics (SRPT) Gets a Buy from Wells Fargo - The Globe and Mail
Why analysts raise outlook for Sarepta Therapeutics Inc. (AB3A) stockJuly 2025 Action & Entry Point Confirmation Alerts - BỘ NỘI VỤ
Sarepta (SRPT) gets FDA approval on new gene therapy study - Investorsobserver
Sarepta Therapeutics, Inc. (SRPT) Stock Forecasts - Yahoo Finance
Tech Stocks Surge Ahead Of Thanksgiving, Robinhood Rallies 10%: What's Moving Markets Wednesday? - Benzinga
Sarepta cleared to test new safety regimen for Duchenne drug - statnews.com
Sarepta to investigate immunosuppressant Elevidys combo to avoid fatal AEs - Yahoo
Sell Rating for Sarepta Therapeutics Due to Risks in ENDEAVOR Study and Expected Share Price Decline - TipRanks
SRPT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit (PR Newswire) - Aktiellt
Local Pharmaceutical Company Earns $200 Million Milestone Payment in Sarepta Partnership Pasadena-based Arrowhead Pharmaceuticals Inc., based in Pasadena, announced it has earned a $200 million milestone payment from Sarepta Therapeutics afte - facebook.com
Sarepta to test immunosuppressive Elevidys regimen in non-ambulatory DMD patients - FirstWord Pharma
Sarepta's Elevidys Gets Boxed Warning for ALI and ALF - CGTLive®
Sarepta gets FDA's go-ahead to study immunosuppressive Elevidys regimen in bid to reverse label restriction - Fierce Pharma
Sarepta's Stock Rises on Positive Updates on DM1 Therapy - Yahoo Finance
Sarepta Therapeutics: Hold Rating Amid ENDEAVOR Progress and Short-term Challenges - TipRanks
Sarepta Secures FDA Nod For Elevidys Study To Reduce Liver Injury Risk - Benzinga
Trading the Move, Not the Narrative: (SRPT) Edition - news.stocktradersdaily.com
Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne - Lelezard
Sarepta Wins FDA Approval To Begin Study On Reducing Liver Injury Risk With Elevidys - Stocktwits
Sarepta (SRPT) Advances with FDA Approval for New Dystrophy Treatment Study - GuruFocus
Sarepta Therapeutics Receives FDA Approval for Dosing Levels for Elevidys Study to Treat Duchenne Muscular Dystrophy - MarketScreener
Sarepta receives FDA approval for ELEVIDYS study with enhanced immunosuppression - StreetInsider
SRPTSarepta Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Bernstein raises Sarepta Therapeutics stock price target to $20 on DMD estimates - Investing.com
Local Pharmaceutical Company Earns $200 Million Milestone Payment in Sarepta Partnership - Pasadena Now
Cautious Outlook on Sarepta Therapeutics Amid Early-Stage Trials and Financial Commitments - TipRanks
Sarepta shares positive safety update on DM1 asset as Arrowhead snares $200M milestone - Fierce Biotech
ELEVIDYS Label Changes and Pipeline Progress Could Be a Game Changer for Sarepta Therapeutics (SRPT) - Sahm
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics - BioSpace
Arrowhead (ARWR) Secures $200M Milestone Payment from Sarepta - GuruFocus
Arrowhead Pharma secures $200M milestone from Sarepta Therapeutics - MSN
Arrowhead Pharmaceuticals to Receive $200 Million Payment From Sarepta Therapeutics for Meeting ARO-DM1 Milestone - MarketScreener
Sarepta advances phase 1/2 study of DM1 treatment, triggers milestone payment By Investing.com - Investing.com South Africa
Sarepta provides progress update for SRP-1003, its treatment for myotonic dystrophy type 1 - MarketScreener
Sarepta advances phase 1/2 study of DM1 treatment, triggers milestone payment - Investing.com
Sarepta advances SRP-1003 trial, triggers $200 million milestone payment - StreetInsider
Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1 - Sarepta Therapeutics
Sarepta terminates Hansa-partnered gene therapy combination trial - Clinical Trials Arena
Tangible book value per share of Sarepta Therapeutics, Inc. – TRADEGATE:AB3A - TradingView
Sarepta Therapeutics (SRPT): Valuation Update Following ELEVIDYS Label Changes and Heightened Safety Warnings - simplywall.st
Is Sarepta Therapeutics Inc. stock overvalued by current metricsGap Down & Low Drawdown Momentum Ideas - newser.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc.SRPT - PR Newswire
In new FDA role, Pazdur will decide the future of Sarepta’s Duchenne drugs - statnews.com
Will Sarepta Therapeutics Inc. (AB3A) stock test record highs in 2025Weekly Gains Summary & Scalable Portfolio Growth Methods - newser.com
Mizuho reaffirms Sarepta Therapeutics stock with Outperform rating - Investing.com
Mizuho reaffirms Sarepta Therapeutics stock with Outperform rating By Investing.com - Investing.com Nigeria
Why Sarepta Therapeutics Inc. (AB3A) stock signals breakout potentialJuly 2025 Action & Verified Swing Trading Watchlist - newser.com
What technical models suggest about Sarepta Therapeutics Inc.’s comeback - newser.com
Sarepta Therapeutics Inc. stock trend forecastJuly 2025 Macro Moves & Smart Allocation Stock Reports - newser.com
[Form 4] Sarepta Therapeutics, Inc. Insider Trading Activity - Stock Titan
Sarepta Therapeutics Inc Stock (SRPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.30%
1.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):